For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Pfizer’s Ibrance Bags Label Update for Tamoxifen Combo in Breast Cancer
January 16, 2024
- Leqembi’s Anticipated EU Approval Delayed into April-June 2024: Eisai
January 15, 2024
- GSK’s Arexvy Hits Market as Japan’s 1st RSV Vaccine
January 15, 2024
- Ono Poised to Overcome Opdivo Patent Cliff and Go Fully Global under New President
January 12, 2024
- Daiichi Sankyo Healthcare to Launch Calonal OTC, Ayumi to Focus on Rx
January 12, 2024
- Santen Curbs Cosopt Mini Shipments after Quake, Nitto Medic to Re-Supply All Products
January 12, 2024
- Japan Ethical Drug Sales Up 2.2% in November: Crecon
January 12, 2024
- Sawai Further Delays Manufacturing Start at Trust Pharmatech Unit
January 11, 2024
- Maruho Nabs Japan Rights to AOBiome’s Eczema Drug
January 11, 2024
- New LLP Coverage Rule Loathed by Off-Patent Drug Makers but Innovative Players Hail Reform
January 10, 2024
- FDA Rejects Astellas’ Gastric Cancer Med over Manufacturing Issues
January 10, 2024
- Shionogi, NTT Data to Build Distribution Platform for Digital Therapeutics
January 10, 2024
- Quake Causes Eye Drug Maker to Stop Shipments Except Refrigerated Meds
January 10, 2024
- MTX Detoxifying Agent Megludase Finally Available in Japan
January 10, 2024
- Leqembi Now Approved in China: Eisai/Biogen
January 10, 2024
- BioCryst Japan to First Focus on Orladeyo Promotion, Eager to Set Up Own Sales Team: Local Head
January 9, 2024
- Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
- Organon Japan Gets Approval for Fertility Med Follistim after Re-Filing
January 9, 2024
- Trelegy Frontrunner in GP Promotion, Dayvigo Defends Title in HP List in October: Intage
January 9, 2024
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…